| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
7,834 |
6,853 |
$410K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
1,294 |
1,128 |
$102K |
| 99215 |
Prolong outpt/office vis |
1,039 |
914 |
$74K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
2,808 |
2,479 |
$64K |
| S9088 |
Services provided in an urgent care center (list in addition to code for service) |
1,055 |
1,005 |
$53K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
655 |
583 |
$37K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
918 |
800 |
$31K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
1,292 |
1,045 |
$22K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
700 |
606 |
$14K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,220 |
1,107 |
$13K |
| 99205 |
Prolong outpt/office vis |
28 |
26 |
$3K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
119 |
100 |
$1K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
13 |
13 |
$1K |
| 99336 |
|
86 |
55 |
$417.26 |
| 99337 |
|
23 |
14 |
$292.61 |
| 81002 |
|
15 |
14 |
$16.20 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
16 |
12 |
$7.84 |
| J3420 |
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg |
37 |
33 |
$1.85 |
| S9083 |
Global fee urgent care centers |
124 |
121 |
$0.00 |